Fluvastatin ['Lescol'] is effective in preventing major adverse cardiac events in patients who have undergone percutaneous coronary intervention (PCI) procedures to relieve angina pectoris or other conditions, according to results from the Lescol Intervention Prevention Study (LIPS) presented at the 51st Annual Scientific Sessions of the American College of Cardiology (ACC) [Atlanta, US; March 2002]. The incidence of such events over a 4-year period was reduced by 22% in patients treated with fluvastatin, compared with placebo.1'This reduction in major heart events - such as dying of heart disease or suffering another heart attack - is quite impressive',said the study's principal investigator, Dr Patrick Serruys from Erasmus University Hospital, Rotterdam, The Netherlands.